Default company panoramic image

Melanovus Oncology

Melanovus Oncology is developing novel products for the treatment of advanced melanoma to make a difference in how it's treated worldwide.

  • Stage Product In Development
  • Industry Biotechnology
  • Location Jensen Beach, FL, USA
  • Currency USD
  • Founded March 2012
  • Employees 3
  • Website

Company Summary

Melanovus Oncology is a late stage pre-clinical company advancing first-in-class treatments for late stage melanoma, which is a serious disease and represents a significant unmet medical need with a $3B market potential in the US. We have an experienced management team operating under a capital efficient model. Phase I could begin in mid-2013. We are seeking $1 million to advance through IND application.


  • Default avatar
    Tomas S Lytle
    President and Chief Executive Officer

    Tom, age 66, is a pharmaceutical and biotechnology executive with a demonstrated track record and over 35 years of progressive experience in commercializing products in multiple markets and therapeutic categories at market-leading companies. He began his extensive career in the healthcare industry at Pfizer in 1971. In 20+ years with that company he gained a broad range of industry and commercial experience in a series of sales, marketing, and ma

  • Default avatar
    Gavin P. Robertson
    Chief Scientific Officer

    Gavin, age 48, is a Professor of Pharmacology, Pathology, Dermatology and Surgery at Penn State University, Director of the Penn State Melanoma Center, and Director of the Foreman Foundation Melanoma Research Laboratory in the Department of Pharmacology and the Penn State Cancer Institute. His research focuses on malignant melanoma. The central goal of his program is to unravel the biology and signaling pathways involved in melanoma tumor develop

  • Default avatar
    Rogerio Neves
    Chief Medical Officer

    Rogerio, age 51, is a Professor of Surgery, Dermatology, Pharmacology and Medicine at Penn State University College of Medicine in Hershey, Pennsylvania. He is the deputy director of the Penn State Hershey Melanoma Center, director of the Skin Oncology Program and clinical science leader of the Melanoma Therapeutics Program of The Penn State Cancer Institute.

    Rogerio received his medical degree from Faculdade de Medicina do ABC in Sao Paulo

  • Default avatar
    Peter Gordon
    Chief Financial Officer and Corporate Secretary

    Peter, age 62, has 25 years of experience in management, finance, and accounting activities. He is also the President of 1st U.S. Capital Markets, Inc., a financial advisory and general management consulting firm. He previously served as a Founder, Board Member, Chief Financial Officer and Corporate Secretary of Neogenix Oncology, Inc., a biotechnology firm developing products for the treatment of pancreatic and colorectal cancer. He served as Vi

  • Default avatar
    Tony Brazzale
    Vice President, Product & Business Development

    Tony, age 38, began his career at Abbott Laboratories in 1996 as a research scientist in the area of medicinal drug discovery. In 1999 he moved to Wyeth to continue his drug development career. He is an inventor on numerous patents and an author of a number of published peer-reviewed journal articles in the areas of chemistry and drug discovery in the antibiotic and women’s health therapeutic areas. He left the lab in 2003 to pursue operations


  • Default avatar
    Mark H. Mirkin